• Basilea outlined an anti-infectives strategy built on partnerships, milestone and royalty income, low commercial spend, limited CAPEX.
• Cresemba global in-market sales reached USD 782 million for April 2025–March 2026, up 27% year on year, marketed in 76 countries.
• Zevtera U.S. launch began in July 2025 via Innoviva Specialty Therapeutics; U.S. market exclusivity runs until April 2034.
• Pipeline priorities include Phase 3 fosmanogepix programs in invasive candidiasis and invasive mold infections; oral ceftibuten-ledaborbactam Phase 3 planned mid-2027.
• Non-dilutive R&D funding totaled about USD 440 million, including about USD 165 million related to Zevtera development and regulatory work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.